Cardiovascular Twitter round-up: Eric Topol’s tweet on AI echocardiogram software top tweet in February 2020

Pharmaceutical Technology lists ten of the most popular tweets on cardiovascular in February 2020, based on data from GlobalData’s Influencer Platform. The top tweets were chosen from influencers as tracked by GlobalData’s Influencer Platform, which is based on a scientific process that works on pre-defined parameters. Influencers are selected after a deep analysis of the influencer’s relevance, network strength, engagement, and leading discussions on new and emerging trends.

Top tweets on cardiovascular in February 2020

1. Eric Topol’s tweet on FDA’s approval of the cardiovascular AI-based software for echocardiograms

Eric Topol, an American cardiologist and scientist, shared an article on the AI-guided imaging acquiring system that can help doctors and medical professionals in taking ultrasound images of the heart, also known as echocardiograms. The technology is developed by San Francisco-based healthcare solutions provider Caption Health. This diagnostic system is expected to meet the shortage of expertise in many hospitals.

What is the longer term impact of #AI-algorithms that guide non-expert (uninitiated) humans to acquire ultrasound images?
1. Yesterday the @US_FDA approved the 1st system to do this for heart images (echocardiography)https://t.co/57fVD8rhzo @statnews by @matthewherper

— Eric Topol (@EricTopol) February 8, 2020

Username: Eric Topol

Twitter handle: @EricTopol

Retweets: 96

Likes: 160

2. Gregg Stone’s tweet on very late stent-related MACE

Gregg Stone, an interventional cardiologist, shared an article on 19 stent randomised controlled trials for detecting the prevalence of stent-related adverse events that occurred after percutaneous coronary intervention (PCI). Though major adverse cardiovascular events (MACE) are believed to occur during the first year after PCI, very late or long-term events were not established.

The analysis revealed that very late stent-related events occurred between one and five years, at the rate of 2% every year with all kinds of stents and with no plateau evident.

Our publ in JACC today – an individual data pooled analysis of 25,032 pts from 19 stent RCTs shows an ongoing ~2%/year risk of stent-related events with all stent types with no plateau evident. Must reduce both long-term stent- & non-stent-related outcomes to improve prognosis. pic.twitter.com/vXUf5RyAtQ

— Gregg W. Stone MD (@GreggWStone) February 10, 2020

Username: Gregg W. Stone

Twitter handle: @GreggWStone

Retweets: 79

Likes: 223

3. Dr Martha Gulati’s tweet on heart health awareness

Dr Martha Gulati, division chief of cardiology for the UA College of Medicine, Phoenix, tweeted on heart health awareness. She states that most women are unaware of the hidden risks associated with heart disease. As a result, regular trials and awareness is important for women.

Tomorrow is #NationalGoRedDay
We go red 👠💃🏻 because:
♥️ Heart disease remains the #1 killer of 💃🏻
♥️ Heart disease remains hidden to many women. 💃🏻don’t always know their risk
♥️ We go red to empower💃🏻 to take charge of their ♥️ & get 💃🏻 into trials #EmpoweRED #GoRedForWomen pic.twitter.com/GlR1Rgj0xb

— Dr. Martha Gulati (@DrMarthaGulati) February 6, 2020

Username: Dr. Martha Gulati

Twitter handle: @DrMarthaGulati

Retweets: 62

Likes: 122

4. Michael Gibson’s tweet on the launch of first-of-its-kind virtual study to improve heart health

Michael Gibson, an interventional cardiologist, researcher and educator, shared an article on the launch of Heartline, a virtual clinical study initiated by Johnson & Johnson and Apple. The collaboration aims to understand whether certain health features in new iPhones and Apple devices can help improve outcomes and reduce the risks of strokes and deaths.

I'm in New York City to announce the launch of #Heartline™, the largest randomized trial to date of 150,000 participants. It's a virtual study designed to explore if a new iPhone App & Apple Watch can help reduce the risk of stroke & death. https://t.co/pFknCYN9x8 pic.twitter.com/fy3NViWOfF

— C. Michael Gibson MD (@CMichaelGibson) February 25, 2020

Username: C. Michael Gibson

Twitter handle: @CMichaelGibson

Retweets: 55

Likes: 188

5. Chris P Gale’s tweet on discontinuing statins for primary cardiovascular prevention at the age of 75 years

Chris P Gale, a consultant cardiologist and professor of cardiovascular medicine, shared an article that found that the discontinuation of Statin, led to a 33% increased risk of hospitalisation for cardiovascular events in 75-year-old primary prevention patients. The French study further stated that additional randomised studies were required to confirm the findings and understand the use of statins for primary prevention in the elderly.

#Statin discontinuation associated with a 33% increased risk of hospitalisation for a #cardiovascular event in 75-year-old primary prevention patients: a French nationwide population-based cohort study @ESC_Journals https://t.co/1MQRHfhsZQ

— Prof Chris P Gale (@cpgale3) January 31, 2020

Username: Prof Chris P Gale

Twitter handle: @cpgale3

Retweets: 54

Likes: 107

6. John P Erwin’s tweet on push-up capacity and subsequent CVD event incidence

John P Erwin, a cardiologist and professor, shared an article on the association between push-up capacities and the lower incidence of cardiovascular disease (CVD). The cohort study on young active men found that 40 or more push-ups were associated with lesser incidence of CVD compared to those able to complete less than 10 push-ups.

Evidence suggests a definite association between increased physical fitness and better heart health and longevity. However, low-cost measures have not been thoroughly studied to evaluate functional capacity and cardiovascular risks, the article stated.

>40 PushUps assoc w significant ⬇️ in incident #CVD event risk c/w those completing < 10 push-ups.

Push-up capacity is a no-cost, fast, & simple measure that may be a usefulobjective clinical assessment tool for evaluating functional capacity & #CVRisk https://t.co/D04YAgWohe

— John P Erwin III MD✭ (@HeartOTXHeartMD) February 13, 2020

Username: John P Erwin III MD

Twitter handle: @HeartOTXHeartMD

Retweets: 44

Likes: 130

7. Sek Kathiresan’s tweet on FDA’s approval of Bempedoic acid

Sek Kathiresan, a physician-geneticist, re-tweeted on the US Food and Drug Administration’s approval of the new lipid-lowering drug, Bempedoic acid. It is first oral, non-statin, LDL-lowering drug that has been approved since 2002. The Bempedoic acid trials conducted on 3,600 patients found that the drug lowers LDL-C by 15.1% in 12 weeks. The drug was also found to lower total cholesterol, reduce major adverse cardiovascular events.

The influencer added that now the world had more options for LDL lowering, including Statin, Ezetimibe, PCSK9i, and Bempedoic acid, with Inclisiran still in the approval stage.

More options for LDL lowering with approval of bempedoic acid today.

“lowered LDL-C by 15.1% at 12 weeks”

So, now we have:
1. Statin (pill qd)
2. Ezetimibe (pill qd)
3. PCSK9i (injection q 2 weeks)
4. Bempedoic acid (pill qd)

Up next:
5. Inclisiran (siRNA injection 2x/year) https://t.co/eMEawhrAcU

— Sek Kathiresan MD (@skathire) February 21, 2020

Username: Sek Kathiresan

Twitter handle: @kathire

Retweets: 40

Likes: 110

8. Dr Deepak Bhatt’s tweet on the degree of benefit of icosapent ethyl in the US

Dr Deepak Bhatt, a cardiologist, shared an article on the results from 3146 patients randomised in the US. The REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl – Intervention Trial) analysis was conducted to understand the benefit of icosapent ethyl in the US. It had been earlier perceived that patients in the US derived lesser benefit that those enrolled outside.

Results of the randomised patients found that the non-US subgroup revealed significant risk reductions from cardiovascular death, nonfatal myocardial infarction, or hospitalisation for unstable angina, while the US subgroup revealed robust reductions across individual as well composite endpoints, including the total number of deaths caused by a heart disease.

REDUCE-IT USA now published in print in Circulation! Mortality reduction seen in this cohort with multiple cardiovascular risk factors. https://t.co/xGZfFOXS6t @DLBhattMD @mmillermd1 @CBallantyneMD @gabrielsteg

— Dr. Deepak L. Bhatt (@DLBHATTMD) February 4, 2020

Username: Dr. Deepak L. Bhatt

Twitter handle: @DLBHATTMD

Retweets: 38

Likes: 130

9. Wayne’s tweet on America having better healthcare systems and cures today

Wayne, a cardiologist, tweeted on America being much healthier today than it was 20 or 30 years ago. The influencer noted that this could be attributed to better healthcare systems, treatments, and cures. However, a video shared by him points at the Affordable Act Care Act of 2010 to take away incentivisations, and forcing more Americans to succumb to preventable diseases.

Can I just say as a cardiologist, it's a great time to be alive. Americas are healthier now than they were 20 or 30 years ago. We have better treatments. We have better cures.https://t.co/CB4nDDLumj

— Wayne (@Toaster_Pastry) February 8, 2020

Username: Wayne

Twitter handle: @Toaster_Pastry

Retweets: 35

Likes: 263

10. Harlan Krumholz’s tweet on the comparative effectiveness of Chlorthalidone versus Hydrochlorothiazide

Harlan Krumholz, a cardiologist and healthcare researcher, shared an article on the relative effectiveness, as well as the safety of Chlorthalidone and Hydrochlorothiazide. A cohort study of 730,255 individuals, found no difference in the effectiveness of both the drugs. However, Hydrochlorothiazide was found to be safer.

The study also found that Chlorthalidone was associated with no significant cardiovascular benefits when compared with hydrochlorothiazide. In fact, its use revealed greater outcomes associated with renal and electrolyte deviations.

Our paper on comparative effectiveness of thiazide diuretics for #hypertension. Similar effectiveness. Hydrochlorothiazide safer. Observational study with remarkably strong methods, large sample. https://t.co/fSGp0gLsoK @OHDSI @suchard_group pic.twitter.com/LeYBsXE8sc

— Harlan Krumholz (@hmkyale) February 17, 2020

Username: Harlan Krumholz

Twitter handle: @hmkyale

Retweets: 35

Likes: 82

Download the full report from
GlobalData's Report Store

View full report

GlobalData is this website’s parent business intelligence company.